It’s only a small-scale project, but it’s exciting to see new funding models being tried out for drug development.
Here on Techdirt we’ve been pretty scathing about the way that Big Pharma develops drugs — often poorly — and then uses patent monopolies to keep prices so high that only rich Westerners can afford them. Of course, it’s easy to complain about the flaws of the current approach, but are there any alternatives? We’ve already covered one — using prizes – and now Carl Levinson points us to another potentially powerful approach: crowdsourcing. It’s already been adopted by ‘Project Marilyn’ to develop a patent-free anti-cancer drug:
The campaign will fund a xenograft experiment, which is the next step in developing the promising anti-cancer compound “9DS”. This experiment needs to be completed before 9DS can move on to clinical trials.
Here are some more details of both the drug and the project:
The drug candidate 9DS was developed at the University of Maryland. The last work done on the drug showed that it had activity against cancer competitive with leading cancer drugs such as taxol. Moreover, 9DS is also likely to have lower side effects than most chemotherapies, since a related compound, SJG-136, seems to have low side effects in early clinical trials.
Project Marilyn involves: production of more 9DS, and submitting 9DS to a xenograft study (‘curing cancer in mice’). This is the next step in drug development and an important one on the way to doing clinical (human) studies. The process we’re seeking to fund should take approximately 6 months. If we receive more funding, we will add stretch goals, such as further preclinical experiments on 9DS, development 9DS analogs, or other exciting anti-cancer ideas.
Of course, even if enough money is raised — at the time of writing, just over a quarter of the crowdfunding target has been pledged — there’s still much more work to be done before the drug can be sold to the public. An article in the Times of San Diego explains what will happen next:
The Latest on: Patent-free drug
[google_news title=”” keyword=”Patent-free drug” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Patent-free drug
- How sham patents are hurting the pharma industryon May 7, 2024 at 3:09 am
The FTC is cracking down on pharma companies filing sham patents in the Orange Book to delay generics competition.
- FTC Targets ‘Junk’ Patent Listings on Ozempic and Other Drugson May 2, 2024 at 2:20 am
The antitrust cop says that the more than 300 patent listings stall generic competition, keeping prices high for diabetes drugs, inhalers and more.
- FTC targets ‘junk patents’ on Ozempic, other top drugson May 1, 2024 at 4:17 am
The move broadens the antitrust regulator’s campaign against allegedly “improper or inaccurate” patent listings by drugmakers to include top-selling medicines for weight loss, diabetes, asthma and ...
- FTC Targets ‘Junk’ Patent Listings on Ozempic and Other Drugson April 30, 2024 at 3:44 pm
The Federal Trade Commission is challenging hundreds of pharmaceutical patent listings in an effort to smooth the path to more affordable alternatives to brand-name drugs—including blockbusters ...
- US challenges 'bogus' patents on Ozempic, other drugs in effort to spur competitionon April 30, 2024 at 2:58 pm
The Federal Trade Commission is challenging patents on 20 brand-name drugs, including the blockbuster weight-loss injection Ozempic ...
- FTC targets more drug patents, going after obesity, diabetes and asthma medicationson April 30, 2024 at 1:13 pm
The new round of letters targets 20 products and follows a push by the FTC last year to go after patents on asthma inhalers, epinephrine pens and other products. In response to last ...
- US challenges 'bogus' patents on Ozempic, other drugs in effort to spur competitionon April 30, 2024 at 11:26 am
Most blockbuster drugs are protected by dozens of patents covering various ingredients ... who create the content with TribLIVE Ad-Free.
- FTC Warns ‘Junk Patents’ Could Make Drugs Like Ozempic Pricier—Here’s Howon April 30, 2024 at 10:55 am
The “bogus” patent listings keep brand name drug prices “artificially high,” regulators said. The FTC sent warning letters to 10 pharmaceutical companies—including Novo Nordisk ...
- US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competitionon April 30, 2024 at 10:03 am
Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practice ...
- FTC cracking down on junk patents in drugs like Ozempicon April 30, 2024 at 7:45 am
In an attempt to curb inaccurate patent listings in the Food and Drug Administration’s “Orange Book,” a list of drugs the FDA has deemed safe and effective, the Federal Trade Commission has ...
via Bing News
